Pentadecapeptide vs Glepaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: BPC-157 Full Sequence, Stable Gastric Pentadecapeptide
Pentadecapeptide almost always means BPC-157, a synthetic 15-amino-acid chain (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. It is one of the most hyped 'healing' peptides online, marketed for tendon, gut, and muscle repair, but here is the catch: essentially all of the supporting evidence is from rats and mice. There is no FDA approval and no completed human clinical trial proving it does any of this.
Also: ZP1848, Zeydovio
Glepaglutide is Zealand Pharma's long-acting GLP-2 analog for short bowel syndrome, built to be injected once or twice a week instead of daily like teduglutide. Its path has been bumpy. The FDA rejected it in December 2024 because the single phase 3 trial only worked at the twice-weekly dose, but Europe went the other way: in September 2026 the EMA's CHMP recommended approval under the name Zeydovio. As of late October 2026 the final European Commission decision is still pending, and the US needs another trial.
Key Comparison Insights
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Glepaglutide has stronger research evidence (Human Trials) compared to Pentadecapeptide (Animal Studies).
Detailed Comparison
| Attribute | Pentadecapeptide | Glepaglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | BPC-157's proposed mechanism is still a hypothesis built mostly on animal work, not settled biology. The most consistent finding is that it appears to promote angiogenesis, the growth of new blood vessels, partly by upregulating the VEGFR2 (vascular endothelial growth factor receptor 2) pathway, which would help explain faster tissue repair. Researchers have also reported effects on the nitric oxide system and interactions with dopaminergic, serotonergic, and adrenergic signaling in rodents, which is sometimes invoked to explain its claimed gut-brain and mood effects. It does not have one clean, identified receptor the way a hormone does, and the molecular details remain unconfirmed in humans. | Glepaglutide activates the GLP-2 receptor in the intestine, the same target as teduglutide, which makes the gut lining grow and absorb more fluid and nutrients. What is different is the delivery. After a subcutaneous injection it forms a depot and is slowly released, mostly as two active metabolites rather than the parent molecule. In a healthy-volunteer study the effective half-life was roughly 88 to 124 hours, long enough to make weekly or twice-weekly dosing plausible. The flip side is the same as the rest of the GLP-2 class: anything that makes gut tissue grow raises questions about polyps and tumors over the long run. |
| Common Dosing | Limited community data available See research protocols | 10 mg twice weekly (trial dose) Twice weekly |
| Administration | Subcutaneous injection | Subcutaneous injection (prefilled pen in the EU filing) |
| Typical Duration | 4-12 weeks typical | 24 weeks in EASE-1, with longer-term extension studies |
| Best Time to Take | Morning and evening (or near injury site timing) | Same days each week (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The preclinical record is genuinely large and fairly consistent: across decades of rat and mouse studies, BPC-157 has accelerated healing of tendon, ligament, muscle, bone, and gut tissue, and protected against ulcers and various toxic insults, with one tendon study (Journal of Applied Physiology, 2011) showing it speeds tendon cell outgrowth, survival, and migration. That sounds impressive until you notice the gap between the lab bench and people. Recent reviews, including a 2025 MDPI literature and patent review and a 2025 narrative review in PMC, state plainly that there is no approved formulation, no validated human dose, and no completed Phase II trial. So while the animal data is real and reproducible, the human evidence is effectively zero, and claims about what it does in people are extrapolation, not proof. It is also banned by the World Anti-Doping Agency, which tells you it is treated as a performance drug, not a vetted medicine. | The main evidence is EASE-1, published in Gastroenterology in April 2025 (Jeppesen and colleagues). It randomized 106 adults with SBS and intestinal failure to glepaglutide 10 mg twice weekly, 10 mg once weekly, or placebo for 24 weeks. Twice weekly cut weekly parenteral support by 5.13 L versus 2.85 L on placebo (p=0.0039), and 65.7% were responders versus 38.9% on placebo. Once weekly (3.13 L) did not reach significance. A handful of patients came off IV support completely, none on placebo. On 19 December 2024 the FDA issued a complete response letter saying there was not enough evidence at the to-be-marketed dose and asked for another trial; Zealand is running EASE-5 to support a US resubmission. Zealand filed in Europe in June 2025 and the CHMP gave a positive opinion on 17 September 2026 for adults with SBS (10 mg prefilled pen). Common side effects listed by the EMA are injection site reactions, abdominal pain, nausea, and vomiting. Bottom line: real phase 3 data, but from a single trial with one of two doses positive, which is exactly why the two regulators disagreed. |
Frequently Asked Questions: Pentadecapeptide vs Glepaglutide
What is the difference between Pentadecapeptide and Glepaglutide?
Pentadecapeptide is a healing peptide that pentadecapeptide almost always means bpc-157, a synthetic 15-amino-acid chain (gly-glu-pro-pro-pro-gly-lys-pro-ala-asp-asp-ala-gly-leu-val) derived from a protein found in human gastric juice. it is one of the most hyped 'healing' peptides online, marketed for tendon, gut, and muscle repair, but here is the catch: essentially all of the supporting evidence is from rats and mice. there is no fda approval and no completed human clinical trial proving it does any of this. Glepaglutide is a healing peptide that glepaglutide is zealand pharma's long-acting glp-2 analog for short bowel syndrome, built to be injected once or twice a week instead of daily like teduglutide. its path has been bumpy. the fda rejected it in december 2024 because the single phase 3 trial only worked at the twice-weekly dose, but europe went the other way: in september 2026 the ema's chmp recommended approval under the name zeydovio. as of late october 2026 the final european commission decision is still pending, and the us needs another trial. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Pentadecapeptide or Glepaglutide?
Neither is universally "better" - the choice depends on your specific goals. Pentadecapeptide is typically used for healing purposes, while Glepaglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Pentadecapeptide and Glepaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Pentadecapeptide and Glepaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.